With $100M in fresh back­ing and a new TCR ini­tia­tive, Athenex launch­es Chi­na JV

A year af­ter John­son Lau out­lined the full mea­sure of his plans for a biotech come­back in an S-1 fil­ing for Athenex $AT­NX, the biotech ex­ec has fol­lowed up with a $100 mil­lion in­vest­ment/loan from Per­cep­tive along with a new Chi­nese joint ven­ture which will set out to en­gi­neer TCRs for can­cer.

The Buf­fa­lo-based com­pa­ny had kept some­thing of a low pro­file, but that’s all long over now as Athenex looks to grab some head­lines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER